Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study
Osteoporosis International,  Clinical Article

Silverman SL et al. – The findings support a sustained anti-fracture effect of bazedoxifene on new vertebral fractures in postmenopausal osteoporotic women and on non-vertebral fractures in the higher-risk subgroup of women.

Methods

  • 4,216 postmenopausal women with osteoporosis enrolled
  • 2-year extension of 3-year, randomized, double-blind, placebo-controlled, phase 3 trial
  • In core study (N=7,492), subjects received bazedoxifene 20 or 40 mg/day, raloxifene 60 mg/day, or placebo
  • Raloxifene arm was discontinued after 3 years; subjects receiving bazedoxifene 40 mg were transitioned to bazedoxifene 20 mg after 4 years
  • 5-year findings reported for bazedoxifene 20 and 40/20 mg and placebo
  • Endpoints included incidence of new vertebral fractures (primary) and non-vertebral fractures, and changes in BMD and bone turnover markers

Results
  • At 5 years, the incidence of new vertebral fractures in the intent-to-treat population was significantly lower with bazedoxifene 20 mg (4.5%) and 40/20 mg (3.9%) versus placebo (6.8%; P<0.05), with relative risk reductions of 35% and 40%
  • Non-vertebral fracture incidence was similar among groups
  • In a subgroup of higher-risk women (n=1,324; femoral neck T-score ≤-3.0 and/or ≥1 moderate or severe or ≥2 mild vertebral fracture[s]), bazedoxifene 20 mg reduced non-vertebral fracture risk versus placebo (37%; P=0.06); combined data for bazedoxifene 20 and 40/20 mg reached statistical significance (34% reduction; P<0.05)
  • Bazedoxifene significantly increased BMD and reduced bone turnover versus placebo (P<0.05) and was generally safe and well tolerated

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Rheumatology Articles

1 Immune fault linked to disease University of Edinburgh College of Medicine News, December 1, 2014

2 A combination of celecoxib and famciclovir is efficacious in the treatment of fibromyalgia: Results of a phase IIa randomized, double-blind, placebo-controlled study American College of Rheumatology News, December 2, 2014    Clinical Article

3 The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: A systematic review and meta-analysis Lupus, November 26, 2014    Evidence Based Medicine    Review Article

4 Coffee or tea consumption and the risk of rheumatoid arthritis: A meta-analysis Clinical Rheumatology, October 15, 2014    Clinical Article

5 Blood test could prevent medication trial and error for rheumatoid arthritis patients Mayo Clinic, November 18, 2014

6 The comparative safety of TNF inhibitors in rheumatoid arthritis - a meta-analysis update of 44 randomized controlled trials American Journal of Medicine, October 6, 2014    Clinical Article

7 Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis Rheumatology, December 8, 2014    Clinical Article

8 Yearly treatment could slow osteoarthritis Monash University News, September 23, 2014

9 Ten common mistakes in the management of lupus nephritis American Journal of Kidney Diseases, January 3, 2014    Clinical Article

10 Tramadol and risk of hospitalization for hypoglycemia McGill University News, December 10, 2014

11 Methotrexate and lung disease in rheumatoid arthritis – A meta-analysis of randomized controlled trials Arthritis & Rheumatism, December 27, 2013    Evidence Based Medicine    Review Article    Clinical Article

12 Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye Mayo Clinic, November 19, 2014

13 Lupus enteritis: Clinical characteristics and predictive factors for recurrence Lupus, December 4, 2014    Clinical Article

14 Safety and efficacy of ifalimumab, an anti IFN-alpha monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus American College of Rheumatology News, November 25, 2014

15 Diagnostic value of the anti-Sa antibody compared with the anti-cyclic citrullinated peptide antibody in rheumatoid arthritis International Journal of Rheumatic Diseases, December 11, 2014    Clinical Article

16 Fish consumption and risk of rheumatoid arthritis: A dose-response meta-analysis Arthritis Research & Therapy, October 8, 2014    Evidence Based Medicine    Review Article

17 Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids Rheumatology, December 10, 2014    Clinical Article

18 Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial Annals of Rheumatic Diseases, November 10, 2014    Clinical Article

19 Electrical stimulation for pain relief in knee osteoarthritis: Systematic review and network meta-analysis Osteoarthritis and Cartilage , December 4, 2014    Evidence Based Medicine    Review Article

20 Current evidence on risk factors for knee osteoarthritis in older adults: A systematic review and meta-analysis Osteoarthritis and Cartilage , December 2, 2014    Evidence Based Medicine    Review Article

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List